Sign In
Buy NVAX
$7.89
-0.0600 (-0.755%)
At Close: Aug 10, 2026
Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock
10:01am, Tuesday, 17'th Mar 2026
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novavax, Inc. (NVAX) Presents at Leerink Global Healthcare Conference 2026 Transcript
06:00pm, Tuesday, 10'th Mar 2026
Novavax, Inc. (NVAX) Presents at Leerink Global Healthcare Conference 2026 Transcript
Novavax, Inc. (NVAX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
04:22pm, Tuesday, 03'rd Mar 2026
Novavax, Inc. (NVAX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now?
10:01am, Tuesday, 03'rd Mar 2026
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
What's Going On With Novavax Stock On Friday?
02:20pm, Friday, 27'th Feb 2026
Novavax Inc. (NASDAQ: NVAX) shares are down on Friday, possibly on profit-taking after the stock rallied on Thursday following the company's announcement of its fourth-quarter and full-year 2025 finan
Novavax: The Bear Case Is Broken, But The Bull Case Needs More Proof
12:11pm, Friday, 27'th Feb 2026
Novavax (NVAX) has transitioned into a royalty-driven model, with Q4 profitability and 73% of revenue from licensing and royalties. NVAX's FY26 revenue guidance of $230M–$270M reflects cleaner, high
Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates
09:30am, Friday, 27'th Feb 2026
NVAX stock jumps 17% after Q4 swings to a surprise profit on strong licensing revenues and lower costs, with sales soaring 67% year over year.
Novavax to Participate in Upcoming Investor Conferences
04:30pm, Thursday, 26'th Feb 2026
GAITHERSBURG, Md., Feb. 26, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), today announced that it will participate in the following upcoming investor conferences: TD Cowen 46 th Annual Health Ca
Novavax, Inc. (NVAX) Q4 2025 Earnings Call Transcript
03:08pm, Thursday, 26'th Feb 2026
Novavax, Inc. (NVAX) Q4 2025 Earnings Call Transcript
COVID-19 Vaccine Maker Novavax Swings To Profit As Sales Climb
02:19pm, Thursday, 26'th Feb 2026
Novavax Inc. (NASDAQ: NVAX) shares are up on Thursday following the company's announcement of its fourth-quarter and full-year 2025 financial results.
Novavax (NVAX) Beats Q4 Earnings and Revenue Estimates
01:16pm, Thursday, 26'th Feb 2026
Novavax (NVAX) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of a loss of $0.66 per share. This compares to a loss of $0.51 per share a year ago.
S&P 500, Nasdaq Struggle Amid AI Rotation Pain
12:05pm, Thursday, 26'th Feb 2026
While the Dow is higher, the Nasdaq and S&P 500 are struggling for gains as AI sentiment dampens
Novavax raises 2026 adjusted revenue outlook on strength in vaccine deals
08:06am, Thursday, 26'th Feb 2026
Novavax raised its adjusted revenue forecast for 2026 on Thursday, as it expects milestone payments from vaccine supply and licensing deals to offset pressure from sagging demand.
Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
08:00am, Thursday, 26'th Feb 2026
Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areas Multiple Material Transfer Agreements signed in 2025 and Q1 2026 with pharmac
Novavax (NVAX) Upgraded to Buy: Here's What You Should Know
01:00pm, Monday, 23'rd Feb 2026
Novavax (NVAX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
